Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of "Moderate Buy" by Analysts

Shares of Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $35.50.

Several research firms have recently issued reports on OPCH. JMP Securities reaffirmed a "market outperform" rating and issued a $36.00 price objective on shares of Option Care Health in a research note on Wednesday. JPMorgan Chase & Co. boosted their target price on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Barrington Research reaffirmed an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a research note on Wednesday, April 30th. Finally, UBS Group upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th.

Option Care Health Price Performance

Shares of NASDAQ:OPCH traded down $0.35 during trading on Tuesday, hitting $31.21. 814,091 shares of the company were exchanged, compared to its average volume of 1,871,012. Option Care Health has a 1-year low of $21.39 and a 1-year high of $35.53. The company has a market capitalization of $5.11 billion, a P/E ratio of 25.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.74. The company has a quick ratio of 1.02, a current ratio of 1.54 and a debt-to-equity ratio of 0.82. The business's 50 day moving average is $32.08 and its 200-day moving average is $30.48.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. Option Care Health's quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS. Equities analysts forecast that Option Care Health will post 1.22 earnings per share for the current year.

Institutional Trading of Option Care Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPCH. Wellington Management Group LLP boosted its stake in shares of Option Care Health by 84.6% in the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock valued at $425,143,000 after purchasing an additional 8,400,208 shares during the last quarter. Durable Capital Partners LP acquired a new stake in Option Care Health during the first quarter worth approximately $122,905,000. Norges Bank acquired a new stake in Option Care Health during the fourth quarter worth approximately $60,219,000. Nuveen LLC acquired a new position in Option Care Health in the first quarter valued at approximately $70,965,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Option Care Health by 6,525,926.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock worth $52,459,000 after buying an additional 1,500,963 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.